Tenax Therapeutics, Inc. · NASDAQ:TENX
Tenax Therapeutics — Technical Presentation (August 2026)
19 slides from Tenax Therapeutics's technical presentation, Aug 10, 2026
Slide 1: LEVEL Clinical Trial Topline Results
LEVEL Clinical Trial Topline Results August 10, 2026 Exhibit 99.2
Slide 2: Today's Agenda
Today’s Agenda Opening RemarksChris Giordano President and CEO LEVEL Topline ResultsStuart Rich, MD CMO KOL ThoughtsSanjiv Shah, MD Northwestern University Path ForwardChris Giordano CEO Q&AChris Giordano President and CEO Stuart Rich, MD CMO Doug Randall CBO Tom Staab CFO Sanjiv Shah, MD Northweste
Slide 3: Forward-Looking Statements
Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements may include information concerning our clinical data, our regulatory plans, ou
Slide 4: Introduction
Introduction Chris Giordano President and CEO, Tenax Therapeutics
Slide 5: What LEVEL Told Us
What LEVEL Told Us WHERE THE TRIAL LANDED *Prespecified analysis; nominal p-values are not adjusted for multiplicity. NT-proBNP: N-terminal pro B-type natriuretic peptide; RVSP: right ventricular systolic pressure; HELP: Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF; 6MWD: 6-minut
Slide 6: Phase 3 LEVEL Clinical Trial Topline Results
Phase 3 LEVEL Clinical Trial Topline Results Stuart Rich, MD CMO, Tenax Therapeutics
Slide 7: LEVEL Study
LEVEL Study PHASE 3 REGISTRATIONAL TRIAL IN US AND CANADA BID: twice a day; TID: three times a day; 6MWD: 6-minute walk distance; RHC: right heart catheterization; PCWP: pulmonary capillary wedge pressure; mPAP: mean pulmonary artery pressure; RAP: right arterial pressure. 1mg oral capsule BID, titr
Slide 8: Patient Demographics
Patient Demographics BASELINE CHARACTERISTICS WERE BROADLY BALANCED ACROSS TREATMENT ARMS BMI: body mass index; 6MWD: 6-minute walk distance; eGFR: estimated glomerular filtration rate; NYHA: New York Heart Association. Characteristic TNX-103 (N=120) Placebo (N=121) Overall (N=241) Age, years, mean
Slide 9: Primary and Key Secondary Endpoints
Primary and Key Secondary Endpoints *N=120 and N=121 for TNX-103 and placebo arms, respectively. 6MWD: 6-minute walk distance; LS: least squares; SE: standard error; SD: standard deviation; KCCQ-TSS: Kansas City Cardiomyopathy Questionnaire-Total Symptom Score; NYHA: New York Heart Association; NS:
Slide 10: Safety
Safety TOLERABILITY DIFFERENCE BETWEEN ARMS; SERIOUS EVENTS AND CLINICAL WORSENING BALANCED CWE: clinical worsening event; AE: adverse event; CV: cardiovascular; IV: intravenous. Adverse event summary TNX-103 (N=120) Placebo (N=121) Any adverse event, n (%) 104 (86.7) 87 (71.9) Treatment-related adv
Slide 11: Confirming Biological Activity Using NT-proBNP
Confirming Biological Activity Using NT-proBNP NT-proBNP FELL IN OVERALL POPULATION *nominal p-value. NT-proBNP: N-terminal pro B-type natriuretic peptide; LS: least squares; CI: confidence interval.. NT-proBNP vs. placebo at Week 12 Geometrics LS mean ratio 0.51 (95% CI: 0.43, 0.60; p < 0.0001*) −
Slide 12: Impressive Reductions in Exploratory Endpoints
Impressive Reductions in Exploratory Endpoints BIOMARKER AND HEMODYNAMIC REDUCTIONS EVEN MORE PRONOUNCED IN PATIENTS WITH HIGHER DISEASE BURDEN *nominal p-value; #95% confidence interval is -6.010, -1.100; HHodges-Lehmann shift estimate. NT-proBNP: N-terminal pro B-type natriuretic peptide; RVSP: ri
Slide 13: Treatment Effect Correlates with Disease Severity
Treatment Effect Correlates with Disease Severity *Post-hoc analysis 6MWD: 6-minute walk distance; LS: least squares; CI: confidence interval. Δ vs. placebo, LS mean 95% CI: 6.0, 46.7; nominal p = 0.0112 + 26.3 meters Δ vs. placebo, LS mean 95% CI: -36.7, 1.7; nominal p = 0.0744 − 17.6 meters Below
Slide 14: Three Disease Burden Markers Correlate with Treatment Effect
Three Disease Burden Markers Correlate with Treatment Effect KEY BASELINE CHARACTERISTICS PREDICT RESPONSE By age Δ 6MWD vs placebo 95% CI Nominal p-value Top tertile (> 74 years), N=77 + 37.6 m 14.7, 60.5 0.0013 Above median (> 71 years), N=124 + 27.1 m 9.9, 44.4 0.0021 Below median (< 71 years), N
Slide 15: What We Learned
What We Learned 6MWD IS BOTH OUR PRIMARY ENDPOINT AND OUR BEST ENRICHMENT CRITERION 6MWD: 6-minute walk distance; HELP: Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF. HELP Phase 2 ~90% of patients enrolled below 400 m Protocol cap 550 m LEVEL Phase 3 50% of patients enrolled below
Slide 16: Additional Thoughts On LEVEL Results
Additional Thoughts On LEVEL Results Sanjiv Shah, MD Director of HFpEF Program Northwestern University Feinberg School of Medicine Principal Investigator on LEVEL Clinical Trial
Slide 17: Next Steps for Tenax
Next Steps for Tenax Chris Giordano President and CEO, Tenax Therapeutics
Slide 18: Where We Go From Here
Where We Go From Here WHAT WE KNOW, WHAT WE WILL DO, AND WHAT IS STILL OPEN PK: pharmacokinetics; NT-proBNP: N-terminal pro B-type natriuretic peptide; RVSP: right ventricular systolic pressure; FDA: Food and Drug Administration; EMA: European Medicines Agency; NDA: New Drug Application; ESC: Europe
Slide 19: Q&A
Q&A Chris Giordano President and CEO, Tenax Therapeutics Stuart Rich, MD CMO, Tenax Therapeutics Sanjiv Shah, MD Northwestern University Doug Randall CBO, Tenax Therapeutics Tom Staab CFO, Tenax Therapeutics
Tenax Therapeutics — Technical Presentation (August 2026) on 6ix